New Market Report: Market and Product Forecasts: HER2-negative/hormone Receptor-positive Breast Cancer - Patent Expiries and Novel Drugs Shape the Market in the Next Decade
The treatment of HER2-negative/hormone receptor-positive breast cancer consists largely of genericized cytotoxic and antihormonal therapies. Avastin (bevacizumab) is currently the only targeted therapy used in this patient population. Patent expiries and the uptake of novel targeted drugs will help shape the market in the next decade, but little change is anticipated in the overall market value.
View full press release